London
· Delayed Price · Currency is GBP · Price in DKKNovo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of GBP 306.88 billion. The enterprise value is 304.88 billion.
| Market Cap | 306.88B |
| Enterprise Value | 304.88B |
Important Dates
The next estimated earnings date is Wednesday, February 5, 2025.
| Earnings Date | Feb 5, 2025 |
| Ex-Dividend Date | Aug 15, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.86% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.16B |
Valuation Ratios
The trailing PE ratio is 29.03.
| PE Ratio | 29.03 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 41.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.36, with an EV/FCF ratio of 35.14.
| EV / Earnings | 28.84 |
| EV / Sales | 10.11 |
| EV / EBITDA | 20.36 |
| EV / EBIT | 21.80 |
| EV / FCF | 35.14 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.47.
| Current Ratio | 0.94 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | 0.42 |
| Debt / FCF | 0.73 |
| Interest Coverage | 825.54 |
Financial Efficiency
Return on equity (ROE) is 88.73% and return on invested capital (ROIC) is 52.81%.
| Return on Equity (ROE) | 88.73% |
| Return on Assets (ROA) | 22.49% |
| Return on Capital (ROIC) | 52.81% |
| Revenue Per Employee | 420,062 |
| Profits Per Employee | 147,048 |
| Employee Count | 64,319 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 1.23 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.52% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +8.52% |
| 50-Day Moving Average | 764.49 |
| 200-Day Moving Average | 869.13 |
| Relative Strength Index (RSI) | 21.73 |
| Average Volume (20 Days) | 680,269 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novo Nordisk had revenue of GBP 30.19 billion and earned 10.57 billion in profits. Earnings per share was 2.37.
| Revenue | 30.19B |
| Gross Profit | 25.56B |
| Operating Income | 14.00B |
| Pretax Income | 13.31B |
| Net Income | 10.57B |
| EBITDA | 14.85B |
| EBIT | 14.00B |
| Earnings Per Share (EPS) | 2.37 |
Balance Sheet
The company has 8.36 billion in cash and 6.36 billion in debt, giving a net cash position of 2.00 billion.
| Cash & Cash Equivalents | 8.36B |
| Total Debt | 6.36B |
| Net Cash | 2.00B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 13.45B |
| Book Value Per Share | 3.02 |
| Working Capital | -1.47B |
Cash Flow
In the last 12 months, operating cash flow was 13.19 billion and capital expenditures -4.52 billion, giving a free cash flow of 8.68 billion.
| Operating Cash Flow | 13.19B |
| Capital Expenditures | -4.52B |
| Free Cash Flow | 8.68B |
| FCF Per Share | n/a |
Margins
Gross margin is 84.66%, with operating and profit margins of 46.37% and 35.01%.
| Gross Margin | 84.66% |
| Operating Margin | 46.37% |
| Pretax Margin | 44.07% |
| Profit Margin | 35.01% |
| EBITDA Margin | 49.19% |
| EBIT Margin | 46.37% |
| FCF Margin | 28.73% |
Dividends & Yields
Novo Nordisk does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | 37.79% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 46.60% |
| Buyback Yield | 0.86% |
| Shareholder Yield | 0.86% |
| Earnings Yield | 3.33% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on September 13, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Sep 13, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Novo Nordisk has an Altman Z-Score of 10.12.
| Altman Z-Score | 10.12 |
| Piotroski F-Score | n/a |